Company: CNTB
Filing Date: 2025-07-18
Form Type: F-6 POS
Source: 0000950127-25-000092
Chunk: 1

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-07-18
Form: F-6 POS
Chunk 1
---
3) |
| American Depositary Shares, each representing one ordinary share of Connect Biopharma Holdings Limited | N/A                     | N/A                                         | N/A                                         | N/A                           |

| 1 | For the purpose of this table only the term “unit” is defined as one American Depositary Share.                                                                                                                                           |
| 2 | Estimated solely for the purpose of calculating the registration fee.  Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of American 
 Depositary Shares.                                                                                                                                                                                                                        |
| 3 | Previously paid.                                                                                                                                                                                                                          |

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the United States Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. This registration statement may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument. EXPLANATORY NOTE This Post-Effective Amendment No. 1 to the Registration Statement on Form F-6 (Registration No. 333-254215) (the “Registration Statement”) of Connect Biopharma Holdings Limited (the “Company”) is being filed solely for the purpose of filing as an exhibit the Amendment to Deposit Agreement between the Company and Deutsche Bank Trust Company Americas (the “Depositary”), as depositary, and the holders and beneficial owners of American Depositary Shares evidenced by American Depositary Receipts issued thereunder to shorten the notice period necessary to terminate the Deposit Agreement from 90 days to 15 days.

PART I

INFORMATION REQUIRED IN PROSPECTUS The prospectus consists of the form of American Depositary Receipt (“Receipt”) included as Exhibits A and B to Amendment to the Deposit Agreement filed as Exhibit (a)(2) to this Post-Effective Amendment No. 1 to the Registration Statement, which is incorporated herein by reference.

| Item 1. | DESCRIPTION OF SECURITIES TO BE REGISTERED CROSS REFERENCE |

| Required Information |                                                                  |                                                                                                              |     | Location in Form of Receipt Incorporated Herein as Prospectus        |
| 1.                   | Name of depositary